The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

As such, the 2nd Peptide Formulation & Delivery Innovation Summit (June 24 - 26, 2025 | Boston, MA) returns as the only ...

The 6th TCR-based Therapies Summit returns as the only forum created solely for TCR experts pioneering best-in-class cell- ...

Despite the revolutionary impact of the original birth control pill, and the decades of medical innovation seen since, ...

Novel analytical methodologies, real-world data (RWD), innovative trial designs, and new technologies are crucial to optimise ...

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...

Other companies use customer reference and patient data to improve operational agility as they launch and scale their first ...